STOCK TITAN
  1. Home
  2. News
  3. IBRX

ImmunityBio, Inc. - $IBRX STOCK NEWS

Welcome to our dedicated page for ImmunityBio news (Ticker: $IBRX), a resource for investors and traders seeking the latest updates and insights on ImmunityBio stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ImmunityBio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ImmunityBio's position in the market.

News
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
Rhea-AI Summary

ImmunityBio, Inc. (NASDAQ: IBRX) has entered into an exclusive global agreement with the Serum Institute of India to supply Bacillus Calmette-Guerin (BCG) for use in combination with ImmunityBio's ANKTIVA.

This collaboration will address the chronic BCG supply shortage issue, providing both standard BCG (sBCG) and next-generation recombinant BCG (iBCG) for approved indications benefiting from ANKTIVA's therapeutic effects.

The agreement aims to enhance immunogenicity and safety compared to standard BCG, improving outcomes for bladder cancer patients globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
Rhea-AI Summary

ImmunityBio's Executive Chairman, Dr. Patrick Soon-Shiong, will discuss the recent FDA approval of ANKTIVA® for use in combination with BCG for non-muscle invasive bladder cancer at the AUA 2024 conference. ANKTIVA's Breakthrough Therapy designation and novel mechanism will be highlighted, offering an alternative therapy to radical surgery for advanced bladder cancer cases. The discussion will focus on transforming cold bladder cancer cells to hot tumors via ANKTIVA's activation of NK and T cells, resulting in durable responses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.12%
Tags
none
-
News
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
Rhea-AI Summary
ImmunityBio, Inc. (NASDAQ: IBRX) announces positive overall survival results in the QUILT 3.055 trial for non-small cell lung cancer patients who did not respond to checkpoint inhibitors. The study showed a nearly double median overall survival compared to standard chemotherapy. ANKTIVA, an immune cell enhancer, displayed efficacy in PD-L1 negative and positive patients, activating natural killer cells and memory T cells. A meeting with the FDA is scheduled to discuss registration for ANKTIVA in combination with checkpoint inhibitors. The company received a $100 million non-dilutive cash infusion, bringing cash-on-hand to $240 million for the launch of ANKTIVA in bladder cancer. ImmunityBio plans to discuss registration plans and clinical trial pipeline during a conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.02%
Tags
none
News
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Rhea-AI Summary
ImmunityBio's ANKTIVA, a first-in-class IL-15 receptor agonist, receives FDA approval as a breakthrough therapy for BCG-unresponsive non-muscle invasive bladder cancer. The therapy activates the body's immune system to target tumor cells, leading to long-lasting complete responses. ANKTIVA in combination with BCG shows durable responses exceeding 47 months, exceeding clinical benchmarks. Availability in the U.S. is expected by mid-May 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.13%
Tags
fda approval
-
News
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
Rhea-AI Summary
ImmunityBio (IBRX) announces promising preclinical data on N-803 and broadly neutralizing antibodies for HIV treatment. Clinical trials underway to test viral load reduction in HIV-infected individuals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.39%
Tags
none
-
News
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
Rhea-AI Summary
ImmunityBio (NASDAQ: IBRX) announces positive results from a Phase 1 pilot study showing N-803 combined with natural killer cells may reduce viral load in HIV patients. All participants experienced a significant decrease in infection levels. The approach was safe and well-tolerated, paving the way for further research in HIV cure-related clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
none
News
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
Rhea-AI Summary
ImmunityBio (IBRX) announces enrollment in a national trial testing Nant Cancer Vaccine for Lynch syndrome individuals to prevent colon and other cancers. The study includes a tri-valent Adenovirus and IL-15 superagonist N-803 to activate immune cells. Lynch syndrome patients are at high risk for various cancers. The trial aims to prevent cancer by targeting cancer-specific proteins and enhancing immune response. Enrollment for the safety portions of the trial is completed, with a total of 186 participants expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
none
-
News
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
Rhea-AI Summary
ImmunityBio, Inc. (IBRX) announces positive Patient-Reported Outcomes (PROs) from the QUILT 3.032 trial of N-803 plus BCG for non-muscle invasive bladder cancer. The PROs indicate stability of physical function and global health in patients who completed questionnaires and reached month 24 on-study, supporting the safety and tolerability of the potential new treatment combination. The FDA is reviewing the Biologics License Application (BLA) for N-803 plus BCG, with a PDUFA date of April 23, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
none
-
News
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million
Rhea-AI Summary
ImmunityBio, Inc. (NASDAQ: IBRX) announced a $320 million royalty financing and equity investment by Oberland Capital, providing financial resources for commercialization efforts and pipeline expansion. The investment is non-dilutive and includes $200 million funded at closing, with the potential for an additional $100 million contingent upon FDA approval of Anktiva® for the treatment of bladder cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
none
News
ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference
Rhea-AI Summary
ImmunityBio, Inc. (NASDAQ: IBRX) to participate in the 35th Annual Piper Sandler Healthcare Conference in New York City on November 28-30, 2023. The presentation will be a fireside chat with Director and Senior Research Analyst Joseph Catanzaro, Ph.D. The webcast link for the event will be available for replay on the company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Stock IBRX logo
ImmunityBio, Inc.

Nasdaq:IBRX

IBRX Rankings

#1093 Ranked by Market Cap
#4795 Ranked by Stock Gains
N/A Ranked by Dividends

IBRX Stock Data

6.07B
145.27M
79.62%
8.85%
8.09%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About IBRX

immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer (‘nk’) and t cells, tumoricidal macrophages, and memory t cells.